Cross-Linked Polyphenol-Based Drug Nano-Self-Assemblies Engineered to Blockade Prostate Cancer Senescence.
Animals
Antineoplastic Agents
/ chemistry
Apoptosis
/ drug effects
Cell Line, Tumor
Cellular Senescence
/ drug effects
Docetaxel
/ chemistry
Forkhead Box Protein O1
/ metabolism
Humans
Male
Mice
Mice, Nude
Nanostructures
/ chemistry
Polyphenols
/ chemistry
Prostatic Neoplasms
/ drug therapy
Receptor, Transforming Growth Factor-beta Type I
/ metabolism
Signal Transduction
/ drug effects
Tannins
/ chemistry
Transplantation, Heterologous
DSAs
apoptosis
docetaxel
nanoassemblies
prostate cancer
senescence
Journal
ACS applied materials & interfaces
ISSN: 1944-8252
Titre abrégé: ACS Appl Mater Interfaces
Pays: United States
ID NLM: 101504991
Informations de publication
Date de publication:
23 Oct 2019
23 Oct 2019
Historique:
pubmed:
26
9
2019
medline:
18
3
2020
entrez:
26
9
2019
Statut:
ppublish
Résumé
Cellular senescence is one of the prevailing issues in cancer therapeutics that promotes cancer relapse, chemoresistance, and recurrence. Patients undergoing persistent chemotherapy often develop drug-induced senescence. Docetaxel, an FDA-approved treatment for prostate cancer, is known to induce cellular senescence which often limits the overall survival of patients. Strategic therapies that counter the cellular and drug-induced senescence are an unmet clinical need. Towards this an effort was made to develop a novel therapeutic strategy that targets and removes senescent cells from the tumors, we developed a nanoformulation of tannic acid-docetaxel self-assemblies (DSAs). The construction of DSAs was confirmed through particle size measurements, spectroscopy, thermal, and biocompatibility studies. This formulation exhibited enhanced
Identifiants
pubmed: 31553876
doi: 10.1021/acsami.9b14738
pmc: PMC8020616
mid: NIHMS1671790
doi:
Substances chimiques
Antineoplastic Agents
0
Forkhead Box Protein O1
0
Polyphenols
0
Tannins
0
Docetaxel
15H5577CQD
Receptor, Transforming Growth Factor-beta Type I
EC 2.7.11.30
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
38537-38554Subventions
Organisme : NCI NIH HHS
ID : K22 CA174841
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA204552
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA206069
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA210192
Pays : United States
Références
Ther Adv Med Oncol. 2017 May;9(5):307-318
pubmed: 28529548
Mol Pharm. 2008 Jul-Aug;5(4):505-15
pubmed: 18672949
J Mater Chem B. 2015 Feb 7;3(5):728-732
pubmed: 32262161
Curr Med Chem. 2010;17(36):4559-77
pubmed: 21062250
Mater Sci Eng C Mater Biol Appl. 2016 Mar;60:84-91
pubmed: 26706510
J Exp Clin Cancer Res. 2019 Jan 23;38(1):29
pubmed: 30674344
Rev Recent Clin Trials. 2018;13(3):226-237
pubmed: 29623850
ChemMedChem. 2007 Jul;2(7):920-42
pubmed: 17530726
Colloids Surf B Biointerfaces. 2016 Aug 1;144:8-20
pubmed: 27058278
Curr Drug Targets. 2017;18(2):135-146
pubmed: 26521777
PLoS One. 2012;7(11):e48871
pubmed: 23173040
Cell Death Discov. 2017 Aug 21;3:17049
pubmed: 28845296
Cancers (Basel). 2018 Aug 25;10(9):
pubmed: 30149628
Med Princ Pract. 2005;14 Suppl 1:35-48
pubmed: 16103712
Int J Oncol. 2015 Sep;47(3):1111-20
pubmed: 26202061
Can Urol Assoc J. 2009 Oct;3(5):369-74
pubmed: 19829727
Acta Pharm Sin B. 2018 Jul;8(4):602-614
pubmed: 30109184
Mol Cancer Ther. 2017 Oct;16(10):2267-2280
pubmed: 28615299
EBioMedicine. 2017 Jul;21:21-28
pubmed: 28416161
J Hepatol. 2007 Feb;46(2):222-9
pubmed: 17069924
Nat Rev Clin Oncol. 2011 Jan;8(1):12-23
pubmed: 20859283
Cell Rep. 2014 Oct 9;9(1):75-89
pubmed: 25263564
Hepatology. 2010 Sep;52(3):966-74
pubmed: 20583212
Cancer Res. 2002 Aug 1;62(15):4499-506
pubmed: 12154061
Mol Cancer. 2011 Oct 07;10:126
pubmed: 21982118
J Colloid Interface Sci. 2019 Feb 1;535:133-148
pubmed: 30292104
Int J Nanomedicine. 2013;8:2927-41
pubmed: 23950643
Nanomedicine (Lond). 2016 Mar;11(6):673-92
pubmed: 27003448
Int J Nanomedicine. 2017 Apr 04;12:2689-2702
pubmed: 28435252
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
J Mater Chem B. 2015 Jan 7;3(1):90-101
pubmed: 32261929
Drug Resist Updat. 2012 Feb-Apr;15(1-2):123-31
pubmed: 22365330
Cancers (Basel). 2018 Jun 14;10(6):
pubmed: 29903994
Biomaterials. 2011 May;32(15):3794-806
pubmed: 21392822
Ann Oncol. 2017 Nov 1;28(11):2658-2669
pubmed: 29045523
J Agric Food Chem. 2010 Jul 28;58(14):8375-9
pubmed: 20583840
Cancer Sci. 2017 Apr;108(4):563-569
pubmed: 28165648
Ther Adv Med Oncol. 2012 Nov;4(6):329-40
pubmed: 23118808
Cancer Res. 2001 Aug 15;61(16):5974-8
pubmed: 11507037
Anticancer Res. 2019 May;39(5):2467-2473
pubmed: 31092441
JAMA Oncol. 2018 Oct 1;4(10):1344-1351
pubmed: 29978216
Br J Radiol. 2015 Oct;88(1054):20150207
pubmed: 25969868
Oncol Rep. 2016 Mar;35(3):1329-39
pubmed: 26752000
Sci Rep. 2019 Feb 22;9(1):2595
pubmed: 30796322
Clin Chim Acta. 2011 Jan 30;412(3-4):358-64
pubmed: 21078312
Mol Pharm. 2018 Jul 2;15(7):2698-2713
pubmed: 29787277
Clin Transl Med. 2017 Dec 11;6(1):44
pubmed: 29230567
Anticancer Agents Med Chem. 2016;16(6):781-9
pubmed: 26555610
Cold Spring Harb Perspect Biol. 2017 Apr 3;9(4):
pubmed: 27920038
J Colloid Interface Sci. 2017 Feb 15;488:258-268
pubmed: 27837716
Clin Cancer Res. 2009 Sep 15;15(18):5794-802
pubmed: 19737960
J Natl Cancer Inst. 2010 Oct 20;102(20):1536-46
pubmed: 20858887
Nature. 2005 Aug 4;436(7051):642
pubmed: 16079833
Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9363-7
pubmed: 7568133
ACS Appl Mater Interfaces. 2014 May 14;6(9):6709-16
pubmed: 24697646
Cancers (Basel). 2018 Mar 07;10(3):
pubmed: 29518944
Am J Pathol. 2004 Jan;164(1):217-27
pubmed: 14695335
Cancer Res. 2001 Aug 1;61(15):5692-6
pubmed: 11479199
Cancer Discov. 2017 Feb;7(2):165-176
pubmed: 27979832
Oncogene. 2003 Oct 20;22(47):7280-95
pubmed: 14576838
J Cell Mol Med. 2017 Apr;21(4):720-734
pubmed: 27862996
EMBO Mol Med. 2018 Sep;10(9):
pubmed: 30012580
Neoplasia. 2004 Jan-Feb;6(1):1-6
pubmed: 15068665
Nature. 2007 Feb 8;445(7128):656-60
pubmed: 17251933
Biomed Pharmacother. 2015 Aug;74:124-32
pubmed: 26349973